Related references
Note: Only part of the references are listed.Impact of 68Gallium prostate-specific membrane antigen tracers on the management of patients with prostate cancer who experience biochemical recurrence
Wei Diao et al.
BJU INTERNATIONAL (2021)
Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis
Fabio Crocerossa et al.
JOURNAL OF UROLOGY (2021)
Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals
Siroos Mirzaei et al.
CURRENT RADIOPHARMACEUTICALS (2021)
Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer
Steven P. Rowe et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer
Bernard H. E. Jansen et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy
Wei Liu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management
Hong Song et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy
Esther Mena et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer
Mark C. Markowski et al.
JOURNAL OF UROLOGY (2020)
Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for 64Cu/67Cu-Based Theranostics in Prostate Cancer
James M. Kelly et al.
MOLECULAR PHARMACEUTICS (2020)
PSMA PET-CT outperforms conventional imaging in high-risk prostate cancer
Clemens Thoma
NATURE REVIEWS UROLOGY (2020)
Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study
Zeinab Paymani et al.
JOURNAL OF CLINICAL MEDICINE (2020)
F-18-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging
Rudolf A. Werner et al.
THERANOSTICS (2020)
The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis
Niranjan J. Sathianathen et al.
WORLD JOURNAL OF UROLOGY (2019)
A phase Ill, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).
Michael J. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
Etienne Rousseau et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
Goncalo Ferreira et al.
CANCER IMAGING (2019)
Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
Giorgio Treglia et al.
CANCERS (2019)
Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
M. Wondergem et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Mark C. Markowski et al.
CLINICAL GENITOURINARY CANCER (2019)
Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics
R. S. Eapen et al.
WORLD JOURNAL OF UROLOGY (2019)
Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up
Stanislav Lazarev et al.
BJU INTERNATIONAL (2018)
Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer
Shi-ming Huang et al.
MEDICINE (2018)
Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease
Jaden D. Evans et al.
PRACTICAL RADIATION ONCOLOGY (2018)
Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging
James Kelly et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
Felix Dietlein et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2017)
Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent
Simon Gauvin et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2017)
PET/CT with C-11-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data
Stefano Fanti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Acquisition with 11C-choline and 18F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis
Finn E. von Eyben et al.
ANNALS OF NUCLEAR MEDICINE (2016)
PSMA-Based Detection of Prostate Cancer Bone Lesions With 18F-DCFPyL PET/CT: A Sensitive Alternative to 99mTc-MDP Bone Scan and Na18F PET/CT?
Steven P. Rowe et al.
CLINICAL GENITOURINARY CANCER (2016)
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT
Christina Bluemel et al.
CLINICAL NUCLEAR MEDICINE (2016)
Current use of PSMA - PET in prostate cancer management
Tobias Maurer et al.
NATURE REVIEWS UROLOGY (2016)
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
Matthias Eiber et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
Susanne Lutje et al.
THERANOSTICS (2015)
Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease
David M. Schuster et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
A. Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option?
Cristina Nanni et al.
NUCLEAR MEDICINE COMMUNICATIONS (2013)
QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies
Penny F. Whiting et al.
ANNALS OF INTERNAL MEDICINE (2011)
2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
Ying Chen et al.
CLINICAL CANCER RESEARCH (2011)
Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy
Paolo Castellucci et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2007)
Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer
Patrick A. Kupelian et al.
UROLOGY (2006)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
SJ Freedland et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Is prostate-specific membrane antigen a multifunctional protein?
AK Rajasekaran et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2005)
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results
KA Roehl et al.
JOURNAL OF UROLOGY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
